Refers to a Pharmaceutical composition comprising: (a) particles of apixaban (4,5,6,7 tetrahydro - - 1 - (4-methoxyphenyl) - 7-oxo-6 - [4 - (2 - oxo - piperidinyl) phenyl] - 1H pyrazolo [3,4-c] pyridin - 3 - carboxamide) Lens Form N - 1 with an average particle size of 85 microns (b) a diluent Farma Ceuticamente acceptable (c) a Surfactant such as Sodium lauryl sulfate.Also referred to a development process of apixaban tablets. Said composition has higher bioavailability and is useful in the treatment of thromboembolic disorders.SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: (A) PARTICULAS DE APIXABAN( 4,5,6,7-TETRAHIDRO-1-(4-METOXIFENIL)-7-OXO-6-[4-(2-OXO-1-PIPERIDINIL)FENIL]-1H-PIRAZOLO[3,4-C]PIRIDIN-3-CARBOXAMIDA ) CRISTALINO DE FORMA N-1 CON UN TAMANO DE PARTICULA PROMEDIO DE 85 MICRAS (B) UN DILUYENTE FARMACEUTICAMENTE ACEPTABLE. (C) UN AGENTE TENSOACTIVO TAL COMO LAURIL SULFATO DE SODIO. REFERIDO ADEMAS A UN PROCEDIMIENTO DE ELABORACION DE TABLETAS DE APIXABAN. DICHA COMPOSICION PRESENTA UNA MAYOR BIODISPONIBILIDAD Y ES UTIL EN EL TRATAMIENTO DE TRANSTORNOS TROMBOEMBOLICOS.
